Fig. 2
From: Collective analysis of the expression and prognosis for LEM-domain proteins in prostate cancer
The prognostic analysis of ANKLE1, EMD, and LEMD2 in prostate cancer. A–C The progress-free interval of ANKLE1, EMD, and LEMD2 mRNA level in prostate cancer patients (Kaplan-Meier plotter, tumor samples: n =499). D–F The overall survival of ANKLE1, EMD, and LEMD2 mRNA level in prostate cancer patients (Kaplan-Meier plotter, tumor samples: n = 499). G–L Time-dependent survival ROC curve analysis of ANKLE1, EMD, and LEMD2 to predict 3-, 5-, and 10-year survival rates